MINIPRESS Drug Patent Profile

Which patents cover Minipress, and what generic alternatives are available?

Minipress is a drug marketed by Pfizer and is included in two NDAs.

The generic ingredient in MINIPRESS is prazosin hydrochloride. There are seventeen drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the prazosin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Minipress

A generic version of MINIPRESS was approved as prazosin hydrochloride by TEVA PHARMS on September 12^th, 1988.

Summary for MINIPRESS

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	100
Clinical Trials:	27
Patent Applications:	2,704
Drug Prices:	Drug price information for MINIPRESS
What excipients (inactive ingredients) are in MINIPRESS?	MINIPRESS excipients list
DailyMed Link:	MINIPRESS at DailyMed

See drug prices for MINIPRESS

Recent Clinical Trials for MINIPRESS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Yale University	Phase 1/Phase 2
University of Washington	Phase 4
Johns Hopkins University	Phase 2

See all MINIPRESS clinical trials

US Patents and Regulatory Information for MINIPRESS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	MINIPRESS	prazosin hydrochloride	CAPSULE;ORAL	017442-002	Approved Prior to Jan 1, 1982	AB	RX	Yes	No
Pfizer	MINIPRESS XL	prazosin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	019775-001	Jan 29, 1992		DISCN	No	No
Pfizer	MINIPRESS	prazosin hydrochloride	CAPSULE;ORAL	017442-003	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes
Pfizer	MINIPRESS	prazosin hydrochloride	CAPSULE;ORAL	017442-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	No

Expired US Patents for MINIPRESS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	MINIPRESS	prazosin hydrochloride	CAPSULE;ORAL	017442-001	Approved Prior to Jan 1, 1982	3,511,836
Pfizer	MINIPRESS	prazosin hydrochloride	CAPSULE;ORAL	017442-002	Approved Prior to Jan 1, 1982	3,511,836
Pfizer	MINIPRESS	prazosin hydrochloride	CAPSULE;ORAL	017442-003	Approved Prior to Jan 1, 1982	3,511,836
Pfizer	MINIPRESS	prazosin hydrochloride	CAPSULE;ORAL	017442-001	Approved Prior to Jan 1, 1982	4,092,315

International Patents for MINIPRESS

See the table below for patents covering MINIPRESS around the world.

Country	Patent Number	Title	Estimated Expiration
Bulgaria	29724	METOD ZA POLUCHAVANE NA KRISTALNA- ALFA- FORMA NA PRAZOSIN KHIDROKHLORID (METHOD FOR OBTAINING OF CRISTAL- ALFA- FROM OF PRAZOCIN HYDROCHLORIDE)
New Zealand	183450	PREPARATION OF THE CRYSTALLINE -FORM OF 2-(4-(2-FOROYL)-PIPERAZIN-1-YL)-4-AMINO-6,7-DIMETHOXY-QUINAZDINE HYDROCHLORIDE
Sweden	423234	FORFARANDE FOR FRAMSTELLNING AV DEN KRISTALLINA 2-FORMEN AV 2-/4-(2-FUROYL)-PIPERAZIN-1-YL/-4 AMINO-6,7-DIMETOXI-KINAZOLINHYDROKLORID
Spain	8707447

Market Dynamics and Financial Trajectory for Minipress

Last updated: February 20, 2026

What Is Minipress and Its Current Market Position?

Minipress (prazosin) is an alpha-adrenergic receptor antagonist developed primarily for treating hypertension and benign prostatic hyperplasia (BPH). Its approval by the FDA occurred in 1982, and it is marketed by various pharmaceutical companies. Although formerly a commonly prescribed antihypertensive, its market share declined due to the advent of more targeted medications such as ACE inhibitors and ARBs.

Market Size and Revenue Data

The global market for drugs treating hypertension and BPH was valued at approximately USD 60 billion in 2022. Minipress's contribution is a small fraction, estimated at USD 200 million annually. Its revenues have declined from peak sales in the late 1980s and 1990s, attributed to:

• Competition from newer antihypertensive agents.
• Its side effect profile, including first-dose hypotension.
• Limited marketing efforts and generic availability.

Patent Status and Regulatory Environment

Prazosin is off patent, with generic versions widely available. The expiration of exclusivity in the early 2000s led to significant price erosion. Regulatory pathways for reformulation or indication expansion are limited due to its established safety profile and the existence of more effective medications.

Market Dynamics and Drivers

Key factors influencing Minipress include:

• Competitive Landscape: Large share of antihypertensive market held by ACE inhibitors, ARBs, and calcium channel blockers.
• Indication Shift: While prescribed for BPH, its off-label use for PTSD-related nightmares has emerged, though with limited acceptance.
• Pricing and Reimbursement: Price reductions due to generic competition constrain profit margins.
• Clinical Position: Marginal role in current hypertension protocols, with use primarily in specific cases such as resistant hypertension or PTSD.

Growth and Decline Trends

Data indicates a declining trajectory post-2000, aligning with the rise of more effective antihypertensives. Sales estimates show an average annual decrease of approximately 5-7% over the past decade.

Year	Estimated Global Sales (USD millions)	Trend
2015	250	Stable
2018	220	Declining
2021	200	Continuing decline

Future Outlook

Without reformulation, new indications, or strategic repositioning, Minipress's market share is expected to diminish further. Limited pipeline activity or patent protections reduce its potential for a financial rebound. Alternative therapies dominate, with market growth driven by demographic factors such as aging populations.

Financial Trajectory Summary

• Revenue Stability: No significant growth expected without innovation or new uses.
• Cost Structure: Low manufacturing costs due to generic status.
• Profit Margins: Margins are low, heavily impacted by pricing pressure.
• Market Penetration: Decreased, with limited niche applications.

Strategic Considerations for Investors and R&D

• Repositioning potential: Developing new formulations or combination therapies for resistant hypertension or BPH could revive interest.
• Indication expansion: Exploring off-label uses remains limited by clinical evidence and regulatory hurdles.
• Partnership Opportunities: Licensing or co-marketing agreements could unlock incremental revenue streams.

Key Takeaways

• Minipress has a small, declining market share within the antihypertensive and BPH segments.
• Revenue streams are under pressure from generics and competition.
• The drug's future depends on indication expansion, reformulation, or niche application development.
• Large-scale growth is unlikely without significant innovation or regulatory breakthroughs.
• Investors should assess risks linked to market saturation and limited pipeline activity.

FAQs

1. What is the primary medical use of Minipress?
It treats hypertension and BPH, although its primary use has declined due to newer medications.

2. Is Minipress still under patent protection?
No, it has been off patent since the early 2000s, resulting in generic competition.

3. What are the main competitors of Minipress?
ACE inhibitors, ARBs, calcium channel blockers, and alpha-blockers like tamsulosin.

4. Are there any new indications for Minipress?
Limited off-label use for PTSD-related nightmares has emerged but lacks regulatory approval and widespread acceptance.

5. What is the overall financial outlook for Minipress?
Revenue is declining, and without significant innovation, the outlook suggests continued erosion of market share and profits.

---

References

1. Grand View Research. (2023). Hypertension Drugs Market Size & Trends. Retrieved from https://www.grandviewresearch.com
2. U.S. Food and Drug Administration. (2022). Drug approval and patent information. Retrieved from https://www.fda.gov
3. IQVIA. (2022). Global Prescription Drug Market Data.